GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Cash Flow from Financing

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Cash Flow from Financing : $4.41 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2018, Parnell Pharmaceuticals Holdings paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $5.63 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $1.22 Mil on other financial activities. In all, Parnell Pharmaceuticals Holdings earned $4.41 Mil on financial activities for the six months ended in Dec. 2018.


Parnell Pharmaceuticals Holdings Cash Flow from Financing Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Cash Flow from Financing Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Cash Flow from Financing
Get a 7-Day Free Trial 29.86 8.76 14.67 -0.02 4.41

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Cash Flow from Financing Get a 7-Day Free Trial 29.86 8.76 14.67 -0.02 4.41

Parnell Pharmaceuticals Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Parnell Pharmaceuticals Holdings's Cash from Financing for the fiscal year that ended in Dec. 2018 is calculated as:

Parnell Pharmaceuticals Holdings's Cash from Financing for the quarter that ended in Dec. 2018 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2018 was $4.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Parnell Pharmaceuticals Holdings's issuance of stock for the six months ended in Dec. 2018 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Parnell Pharmaceuticals Holdings's repurchase of stock for the six months ended in Dec. 2018 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Parnell Pharmaceuticals Holdings's net issuance of debt for the six months ended in Dec. 2018 was $5.63 Mil. Parnell Pharmaceuticals Holdings received $5.63 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Parnell Pharmaceuticals Holdings's net issuance of preferred for the six months ended in Dec. 2018 was $0.00 Mil. Parnell Pharmaceuticals Holdings paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Parnell Pharmaceuticals Holdings's cash flow for dividends for the six months ended in Dec. 2018 was $0.00 Mil. Parnell Pharmaceuticals Holdings received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Parnell Pharmaceuticals Holdings's other financing for the six months ended in Dec. 2018 was $-1.22 Mil. Parnell Pharmaceuticals Holdings spent $1.22 Mil on other financial activities.


Parnell Pharmaceuticals Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.